Fate Therapeutics (FATE) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Redwire Corporation (RDW) Tops Q3 EPS by 3c, Misses on Revenue; Offers FY26 Revenue Guidance
- Western Midstream Partners, LP (WES) Misses Q3 EPS by 14c; reaffirms guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
